ArticleJournal of medical virology2023
Gold nanoparticle conjugate-based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS-CoV-2 in clinical samples using a smartphone-based application.
Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 79 citations in OpenAlex.
- Amplified aggregation-induced emission via donor-acceptor-donor molecular architecture: a high-sensitivity lateral flow immunoassay platform.Journal of nanobiotechnology · 2026Article
- A Rational Optimization Approach for the Development of a Multiplexed Lateral Flow Immunoassay: Detection of Nonepithelial Ovarian Cancer Markers in Human Serum.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A red/blue bicolor lateral flow immunoassay for simultaneous detection of two enteroviruses based on duplex RT-LAMP.Frontiers in microbiology · 2026Article
- Demonstration and structural basis of a therapeutic DNA aptamer for SARS-CoV-2 spike protein detection.Biosensors & bioelectronics · 2025Article
- Nanopore-based sensing for biomarker detection: from fundamental principles to translational diagnostics.Journal of nanobiotechnology · 2025Review
- Black palladium nanoparticle-based lateral flow immunoassay for cardiovascular disease diagnosis.RSC advances · 2025Article
- Integrated Ultrasound-Enrichment and Machine Learning in Colorimetric Lateral Flow Assay for Accurate and Sensitive Clinical Alzheimer's Biomarker Diagnosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Highly sensitive multiplexed colorimetric lateral flow immunoassay by plasmon-controlled metal-silica isoform nanocomposites: PINs.Nano convergence · 2024Article
- Optical lateral flow assays in early diagnosis of SARS-CoV-2 infection.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- The development of a novel zeolite-based assay for efficient and deep plasma proteomic profiling.Journal of nanobiotechnology · 2024Article
- Impact of nanotechnology on conventional and artificial intelligence-based biosensing strategies for the detection of viruses.Discover nano · 2023Review
- An Integrated Approach to Improve the Assay Performance of Quantum Dot-Based Lateral Flow Immunoassays by Using Silver Deposition.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023Article
- Updates on the Biofunctionalization of Gold Nanoparticles for the Rapid and Sensitive Multiplatform Diagnosis of SARS-CoV-2 Virus and Its Proteins: From Computational Models to Validation in Human Samples.International journal of molecular sciences · 2023Review
- A Systematic Review on the Advanced Techniques of Wearable Point-of-Care Devices and Their Futuristic Applications.Diagnostics (Basel, Switzerland) · 2023Review
- Gold nanoparticle conjugate-based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS-CoV-2 in clinical samples using a smartphone-based application.Journal of medical virology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has emphasized the need for development of a rapid diagnostic device for the effective treatment and its mitigation. Lateral flow immunoassay (LFIA) belongs to a class of diagnostic devices, which has the benefit of providing quick results, easy to handle, low cost, and on-site applicable. So far, several LFIA has been developed for the detection of infectious severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), however, only a few of them are antigen (Ag)-based. Here, we describe an antibody (Ab)-labeled gold nanoparticles (AuNPs)-based LFIA (AuNPs-LFIA) for the detection of Receptor-Binding Domain (RBD) of SARS-CoV-2. For this, RBD Ab of SARS-CoV-2 was conjugated with the AuNPs, which served as a detecting probe. The fabricated LFIA strip was optimized for different parameters such as membrane pore size, blocking conditions, Ab coating concentration, and conjugate incubation. The optimized LFIA strips were validated in spiked buffer samples and the optimal limit of detection was found to be 1 ng/ml, which was confirmed by a smartphone-based application. Moreover, the developed AuNPs-LFIA strips effectively detected RBD Ag in 100 clinical samples with 94.3% sensitivity and 90.9% specificity in clinical samples when compared with the gold standard (RT-PCR). The fabricated LFIAs are reported to have storage stability of up to 21 days at 4°C and room temperature (RT). Hence, the developed LFIA can be used as a portable, cost-effective diagnostic device for rapid detection of SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.